Formulation, Statistical Optimization And In Vitro Ex Vivo Characterization Of Enteric Coated Nanocarriers For Enhanced Oral Bioavailability Of A Bio-Pharmaceutically Challenged Drug

Authors

  • Subhranshu Panda
  • Shubham Tikait
  • Swati Deshmukh

Keywords:

Rifaximin, Solid lipid nanoparticles, Enteric coating, Eudragit L100, Box–Behnken design, Quality by Design, Oral bioavailability, Controlled release, Pharmacokinetics, BCS Class II drug

Abstract

Rifaximin, a Biopharmaceutics Classification System (BCS) Class II drug, exhibits poor aqueous solubility and limited systemic bioavailability following oral administration. The present study aimed to develop and optimize rifaximin-loaded enteric-coated solid lipid nanoparticles (RFN-EC-SLN) to enhance its oral absorption and therapeutic performance. A Quality by Design (QbD)-based Box–Behnken Design (BBD) approach was employed to optimize formulation variables, including lipid, surfactant, and polymer concentrations, with particle size, entrapment efficiency, and drug release as critical quality attributes.

The optimized formulation (F6) demonstrated a mean particle size of 154 ± 2.6 nm, PDI of 0.21 ± 0.03, zeta potential of +17.5 ± 0.04 mV, and high entrapment efficiency (82.0 ± 1.6%). In vitro release studies revealed minimal drug release under gastric conditions (pH 1.2) and sustained release up to 86.0 ± 2.4% at intestinal pH (6.8), following zero-order kinetics (R² = 0.989). Stability studies conducted under accelerated conditions confirmed the physicochemical stability of the formulation.

Acute toxicity evaluation in Wistar rats showed no mortality, behavioral abnormalities, or significant hematological and biochemical alterations, confirming systemic safety. Pharmacokinetic studies demonstrated significantly enhanced absorption of the SLN formulation, with increased Cmax, nearly two-fold higher AUC, prolonged half-life, and relative bioavailability of 159.3% compared to conventional rifaximin suspension.

Overall, the developed enteric-coated SLN system effectively improved the solubility, intestinal protection, and oral bioavailability of rifaximin, highlighting its potential as a promising delivery platform for biopharmaceutically challenged drugs..



Downloads

Download data is not yet available.

References

1. Jain AK, Das M, Swarnakar NK, Jain S. Engineered nanoparticles for oral delivery of poorly soluble drugs: challenges and strategies. Expert Opin Drug Deliv. 2011;8(6):753-766. doi:10.1517/17425247.2011.565743.

2. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012;64(6):557-570. doi:10.1016/j.addr.2011.12.009.

3. Mercuri A, Passerini N, Hadrich G. Enteric-coated nanoparticles for oral delivery of lipophilic drugs: challenges and opportunities. Drug Discov Today. 2022;27(1):218-234. doi:10.1016/j.drudis.2021.09.003.

4. Mohanpuria P, Rana NK, Yadav SK. Biosynthesis of nanoparticles: Technological concepts and future applications. Journal of Nanoparticle Research. 2008;10(3):507-517.

5. Hua S. Advances in oral drug delivery for regional targeting in the gastrointestinal tract: influence of physiological, pathophysiological, and pharmaceutical factors. Front Pharmacol. 2020;11:524. doi:10.3389/fphar.2020.00524.

6. Sastry SV, Nyshadham JR, Fix JA. Recent technological advances in oral drug delivery: a review. Pharm Sci Technol Today. 2019;3(4):138-145. doi:10.1016/S1461-5347(00)00247-9.

7. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation, and state-of-the-art. J Control Release. 2016;240:504-526. doi:10.1016/j.jconrel.2016.06.016.

8. Vivero-Escoto JL, Slowing II, Trewyn BG, Lin VS. Mesoporous silica nanoparticles for intracellular controlled drug delivery. Small. 2010;6(18):1952-1967.

9. Mittal G, Sahana DK, Bhardwaj V, Ravi Kumar MNV. Enteric-coated nanoparticles for oral drug delivery. In: Nanoparticulate Drug Delivery Systems. New York: Informa Healthcare; 2012. p. 135-158.

10. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology. 2007;2(12):751-760.

11. Zhang L, Wang S, Zhang M, Sun J. Nanoparticle-based oral drug delivery systems for poorly soluble drugs: design, optimization, and in-vivo evaluation. Int J Pharm. 2020;587:119669. doi:10.1016/j.ijpharm.2020.119669.

12. Patel V, Agrawal YK, Saraf S. Enteric-coated nanoparticles for targeted oral delivery of a poorly water-soluble drug: formulation and pharmacokinetic assessment. Drug Deliv Transl Res. 2019;9(4):789-801. doi:10.1007/s13346-019-00632-3.

13. Garg NK, Singh B, Jain A, Sharma R. Development and optimization of enteric-coated nanoparticles for enhanced oral bioavailability of a BCS Class II drug. J Nanopart Res. 2018;20:156. doi:10.1007/s11051-018-4257-8.

14. Yadav D, Kumar N. Formulation and characterization of enteric-coated polymeric nanoparticles for pH-sensitive delivery of a poorly soluble anticancer drug. AAPS PharmSciTech. 2017;18(6):2187-2196. doi:10.1208/s12249-016-0696-7.

15. Singh A, Bajpai M. Optimization of Eudragit-based enteric nanoparticles for colon-targeted delivery of a hydrophobic drug using Box-Behnken design. Drug Dev Ind Pharm. 2016;42(8):1316-1327. doi:10.3109/03639045.2015.1135939.

16. Khan S, Batchelor H, Hanson P, Perrie Y, Mohammed AR. Enteric-coated nanoparticles for the oral delivery of poorly soluble drugs: formulation and in vitro evaluation. Eur J Pharm Sci. 2021;159:105715. doi:10.1016/j.ejps.2021.105715.

17. Liu Y, Wang Y, Yang J, Zhang H, Gan L. pH-sensitive polymeric nanoparticles for improved oral delivery of a poorly water-soluble drug: design, optimization, and in vivo pharmacokinetics. Int J Nanomedicine. 2020;15:5789-5802. doi:10.2147/IJN.S259525.

18. Sharma G, Thakur K, Raza K, Singh B. Enteric-coated chitosan-based nanoparticles for colon-targeted delivery of cyclosporine A: formulation, optimization, and in vivo evaluation. JMicroencapsul. 2019;36(3):234-246. doi:10.1080/02652048.2019.1622599.

19. Gonçalves LMD, Maestrelli F, Mura P, Cirri M. Development of solid lipid nanoparticles and enteric-coated nanoparticles for oral delivery of a poorly soluble drug: comparative study. Pharm Dev Technol. 2018;23(7):718-726. doi:10.1080/10837450.2017.1362433.

20. Alai MS, Lin WJ, Pingale SS. Application of polymeric nanoparticles and micelles in the delivery of poorly soluble drugs: a review. J Nanosci Nanotechnol. 2017;17(4):2304-2317. doi:10.1166/jnn.2017.12825.

21. Beloqui A, Coco R, Alhouayek M, Solinís MÁ, Rodríguez-Gascón A, Muccioli GG. Budesonide-loaded nanoparticles with pH-sensitive coating for improved mucosal drug delivery in ulcerative colitis. Nanomedicine. 2016;11(6):616-628. doi:10.2217/nnm.15.218.

22. Zhang X, Wu W. Ligand-mediated active targeting for enhanced oral absorption of poorly soluble drugs. Adv Drug Deliv Rev. 2015;95:104-115. doi:10.1016/j.addr.2015.09.004.

23. Taheri A, Almasri R, Wignall A, Schultz HB, Elz AS, Ariaee A, et al. Enhancing the pharmacokinetics of abiraterone acetate through lipid-based formulations: Addressing solubility and food effect challenges. Drug Deliv Transl Res. 2024.

24. Shah S, Famta P, Vambhurkar G, Sharma A, Mourya A, Srinivasarao DA, et al. Exploration of abiraterone acetate-loaded nanostructured lipid carriers for bioavailability improvement and circumvention of fast-fed variability. Drug Deliv Transl Res. 2025;15:1074–1091.

25. Schultz HB, Meola TR, Thomas N, Prestidge CA. Oral formulation strategies to improve the bioavailability and mitigate the food effect of abiraterone acetate. Int J Pharm. 2020;577:119069.

26. Schultz HB, Wignall AD, Thomas N, Prestidge CA. Enhancement of abiraterone acetate oral bioavailability by supersaturated-silica lipid hybrids. Int J Pharm. 2020;582:119264.

27. Larsen AT, Ohlsson AG, Polentarutti B, Barker RA, Phillips AR, Abu-Rmaileh R, et al. Oral bioavailability of cinnarizine in dogs: Relation to SNEDDS droplet size, drug solubility and in vitro precipitation. Eur J Pharm Sci. 2013;48:339–350.

28. Brogmann B, Beckert T. Enteric targeting through enteric coating. Drugs Pharm Sci. 2001;115:1–30.

29. Joyce P, Tan A, Whitby CP, Prestidge CA. The role of porous nanostructure in controlling lipase-mediated digestion of lipid loaded into silica particles. Langmuir. 2014;30:2779–2788.

30. Joyce P, Dening TJ, Gustafsson H, Prestidge CA. Modulating the lipase-mediated bioactivity of particle-lipid conjugates through changes in nanostructure and surface chemistry. Eur J Lipid Sci Technol. 2017;119:1700213.

31. Joyce P, Kempson I, Prestidge CA. QCM-D and ToF-SIMS investigation to deconvolute the relationship between lipid adsorption and orientation on lipase activity. Langmuir. 2015;31:10198–10207.

32. Joyce P, Kempson I, Prestidge CA. Orientating lipase molecules through surface chemical control for enhanced activity: A QCM-D and ToF-SIMS investigation. Colloids Surf B Biointerfaces. 2016;142:173–181.

33. Stappaerts J, Geboers S, Snoeys J, Brouwers J, Tack J, Annaert P, et al. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: In vitro, rat in situ and human in vivo studies. Eur J Pharm Biopharm. 2015;90:1–7.

34. Acharya M, Gonzalez M, Mannens G, De Vries R, Lopez C, Griffin T, et al. A phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects. Xenobiotica. 2013;43:379–389.

35. Van Speybroeck M, Mellaerts R, Mols R, Do Thi T, Martens JA, Van Humbeeck J, et al. Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica. Eur J Pharm Sci. 2010;41:623–630.

36. Patra CN, Priya R, Swain S, Jena GK, Panigrahi KC, Ghose D. Pharmaceutical significance of Eudragit: A review. Future J Pharm Sci. 2017;3:33–45.

37. Nguyen HT, Van Duong T, Taylor LS. Impact of gastric pH variations on the release of amorphous solid dispersion formulations containing a weakly basic drug and enteric polymers. Mol Pharm. 2023;20:1681–1695.

38. Nguyen HT, Van Duong T, Taylor LS. Enteric coating of tablets containing an amorphous solid dispersion of an enteric polymer and a weakly basic drug: A strategy to enhance in vitro release. Int J Pharm. 2023;642:123139.

39. Qin Y, Xiao C, Li X, Huang J, Si L, Sun M. Enteric polymer-based amorphous solid dispersions enhance oral absorption of the weakly basic drug nintedanib via stabilization of supersaturation. Pharmaceutics. 2022;14:1830.

40. Angi R, Jordán T, Basa-Dénes O, Solymosi T, Ötvös Z, Glavinas H, et al. Complexes of abiraterone acetate, process for the preparation thereof and pharmaceutical compositions containing them. US Patent 10,668,016. 2 June 2020.

41. Won JH, Jin M, Na YG, Song B, Yun TS, Hwang YR, et al. A combinative strategy for improving the intestinal stability and cellular absorption of curcumin by enteric coating of optimized nanostructured lipid carriers. J Drug Deliv Sci Technol. 2023;89:105108.

42. Hosny KM. Alendronate sodium as enteric-coated solid lipid nanoparticles: Preparation, optimization, and in vivo evaluation to enhance its oral bioavailability. PLoS One. 2016;11:e0154926.

43. Sahu KK, Kaurav M, Pandey RS. Chylomicron-mimicking solid lipid nanoemulsions encapsulated enteric minicapsules targeted to colon for immunization against hepatitis B. Int Immunopharmacol. 2019;66:317–329.

44. Li C, Zhou K, Chen D, Xu W, Tao Y, Pan Y, et al. Solid lipid nanoparticles with enteric coating for improving stability, palatability, and oral bioavailability of enrofloxacin. Int J Nanomedicine. 2019;14:1619–1631.

45. Liu K, Liu W, Dong Z, Zhang L, Li Q, Zhang R, et al. Translation of ionic liquids to enteric nanoparticles for facilitating oral absorption of cyclosporine A. Bioeng Transl Med. 2023;8:e10405.

46. Joyce P, Allen CJ, Alonso MJ, Ashford M, Bradbury MS, Germain M, et al. A translational framework to deliver nanomedicines to the clinic. Nat Nanotechnol. 2024;19:1597–1611.

47. Hosny KM, Osama A, Al-Abdaly R. Enteric-coated alendronate sodium nanoliposomes: a novel formula to overcome barriers for the treatment of osteoporosis. Expert Opin Drug Deliv. 2013;10(6):741–746. doi:10.1517/17425247.2013.799136.

48. Meyyanathan SN, Muralidharan S, Rajan S, Gopal K, Suresh B. A simple sample preparation with HPLC-UV method for estimation of amlodipine from plasma: Application to bioequivalence study. Open Chem Biomed Methods J. 2008;1:22–27.

49. Valliappan K, Kannan K, Sivakumar T, Manavalan R. Enantiospecific pharmacokinetic studies on ketoprofen in tablet formulation using indirect chiral HPLC analysis. J Appl Biomed. 2006;4:153–161.

50. Teply BA, Tong R, Jeong SY, Luther G, Sherifi I, Yim CH. Charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules. Biomaterials. 2008; 29:1216–1223

Downloads

Published

2025-10-15

How to Cite

1.
Panda S, Tikait S, Deshmukh S. Formulation, Statistical Optimization And In Vitro Ex Vivo Characterization Of Enteric Coated Nanocarriers For Enhanced Oral Bioavailability Of A Bio-Pharmaceutically Challenged Drug. J Neonatal Surg [Internet]. 2025 Oct. 15 [cited 2026 Apr. 14];14(32S):10555-70. Available from: https://jneonatalsurg.com/index.php/jns/article/view/10019

Issue

Vol. 14 No. 32S (2025): Journal of Neonatal Surgery

Section

Original Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

  • Adapt — remix, transform, and build upon the material for any purpose, even commercially.

Terms:

  • Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.